290 / 1138
Rociletinib is an irreversible, highly selective TKI
of mutations of EGFR (activating and T790M)
•
72 patients, median age 59; 14% Asian
•
Objective response rate in 46 patients with T790M-
positive disease was
59%
(95% CI 45 to 73)
•
Median PFS not reached, estimated >12 months
Sequist L, NEJM 201
Rociletinib in T790 EGFR-mutant NSCLC